880 Shares in Catalent, Inc. (NYSE:CTLT) Purchased by Sentry Investment Management LLC

Sentry Investment Management LLC purchased a new stake in Catalent, Inc. (NYSE:CTLT) during the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 880 shares of the company’s stock, valued at approximately $53,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in CTLT. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in Catalent during the 2nd quarter worth $42,000. Longfellow Investment Management Co. LLC raised its stake in shares of Catalent by 45.7% in the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after purchasing an additional 305 shares in the last quarter. GAMMA Investing LLC raised its stake in Catalent by 25.9% during the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after buying an additional 212 shares in the last quarter. Intact Investment Management Inc. bought a new position in Catalent during the third quarter worth $73,000. Finally, Livforsakringsbolaget Skandia Omsesidigt boosted its holdings in shares of Catalent by 1,400.0% in the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,500 shares of the company’s stock valued at $91,000 after buying an additional 1,400 shares during the period.

Insider Activity

In related news, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the transaction, the insider now directly owns 36,304 shares in the company, valued at approximately $2,177,150.88. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.31% of the company’s stock.

Catalent Stock Performance

CTLT stock opened at $58.48 on Wednesday. The company has a market capitalization of $10.61 billion, a price-to-earnings ratio of -10.65, a P/E/G ratio of 2.06 and a beta of 1.16. The firm has a 50 day moving average of $60.03 and a two-hundred day moving average of $58.02. The company has a quick ratio of 1.96, a current ratio of 2.52 and a debt-to-equity ratio of 1.35. Catalent, Inc. has a 12 month low of $32.38 and a 12 month high of $61.20.

Catalent (NYSE:CTLT) last posted its earnings results on Thursday, August 29th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.44 by $0.13. The firm had revenue of $1.30 billion for the quarter, compared to the consensus estimate of $1.23 billion. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. As a group, equities analysts anticipate that Catalent, Inc. will post 0.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on CTLT shares. Royal Bank of Canada reissued a “sector perform” rating and set a $63.50 price target on shares of Catalent in a report on Thursday, July 11th. Robert W. Baird reiterated a “neutral” rating and issued a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. William Blair restated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. StockNews.com initiated coverage on Catalent in a report on Saturday, October 12th. They set a “hold” rating on the stock. Finally, Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Nine investment analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $59.83.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.